Please login to the form below

Not currently logged in
Email:
Password:

Blow for Wyeth Tygacil application

Wyeth Europa has withdrawn its application to approve Tygacil for extended uses in the European market.

Wyeth Europa has withdrawn its application to approve Tygacil for extended uses in the European market.

Tygacil (tigecycline) is currently approved for the treatment of complicated skin, soft tissue and intra-abdominal infections. Wyeth had hoped that the drug would be given further indication to treat patients with community-acquired pneumonia (CAP).

The Committee for Medicinal Products for Human use (CHMP) said not enough critically ill patients were included in pivotal trials to prove the drugs efficacy and safety, leaving reviewers unable to render an informed decision. Subsequently, Wyeth withdrew the application for extended marketing authorisation from the European Medicines Agency (EMEA).

Dr Gary Stiles, executive vice-president and chief medical officer of Wyeth Pharmaceuticals, said: "We are disappointed that we were not able to allay the concerns of the CHMP and are evaluating the appropriate next steps to take in Europe."

Wyeth filed a supplemental new drug application (ND) to the US Food and Drug Administration (FDA) in October 2007 for the same treatment indication. An FDA decision is expected in the second quarter of 2008 and outcomes of regulatory reviews are pending in Australia, Brazil, Canada, Switzerland and India.

"We believe that the clinical trial data submitted to the FDA, as well as other regulatory authorities around the world, demonstrate the safety and efficacy of Tygacil for the proposed CAP indication," Stiles concluded.

At present, Tygacil is approved for therapeutic use patients with CAP in the Philippines and Thailand.

25th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics